BMJ open

Testing the safety and effectiveness of bezisterim for adults with long COVID in a triple-blind, placebo-controlled trial

Updated

Abstract

Long COVID is associated with prolonged neurological symptoms, including cognitive impairment and sleep disturbances.

  • Symptoms of Long COVID may arise from ongoing neuroinflammation linked to a viral reservoir.
  • Activation of other viruses and prolonged inflammatory responses could contribute to symptom persistence.
  • The viral Spike protein may stimulate proinflammatory signaling through specific receptors in the brain.
  • Bezisterim (NE3107), an anti-inflammatory compound, may inhibit neuroinflammation driven by these processes.
  • This compound is being developed for conditions where similar inflammation is involved in cognitive decline.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Competing interests: PM, CR, CA and JY are employees and shareholders of BioVie Inc. MJP, LM, SOQ and CMP have received consulting fees from BioVie Inc. SH-YC has received consulting fees from Grace Therapeutics. CMP is a consultant and an employee of Biotechant Solutions LLC. JMP is an employee of BioVie Inc., is a shareholder, has employee stock options, and has the following patents approved or pending: BVIE.020WO, BVIE.028PR. Unrelated to this submitted work, MJP has received consulting fees from Gilead Sciences, AstraZeneca, Apellis Pharmaceuticals and BioNTech, and research support from Aerium Therapeutics and Shionogi.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free